Naratriptan Accord Healthcare (Naratriptan Hydrochloride)

Naratriptan, the active ingredient in Naratriptan Accord Healthcare, is a Triptan (5‑HT1B/1D receptor agonist) presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks, providing relief of headache and associated symptoms in adult patients.

GNH USA supplies Naratriptan Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet the needs of healthcare providers across multiple regions.

Naratriptan acts on the trigeminovascular pathway to relieve migraine symptoms.

Migraine with aura: provides rapid relief of headache, photophobia, phonophobia and associated nausea. Migraine without aura: aborts the attack and reduces intensity of pain and associated symptoms. Acute migraine attack: enables patients to achieve functional recovery within a few hours.

Naratriptan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Chest discomfort or tightness - Flushing or warmth sensation - Dizziness or light‑headedness - Nausea

Serious or Rare Side Effects: - Coronary artery spasm or myocardial ischemia - Serotonin syndrome, especially with other serotonergic drugs

When prescribing Naratriptan, consider the following precautions.

Cardiovascular assessment: evaluate history of coronary artery disease before prescribing. Concomitant serotonergic drugs: avoid use with other serotonergic agents to reduce serotonin syndrome risk. Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. Driving and machinery: caution advised if dizziness or visual disturbances occur. Renal or hepatic impairment: dose adjustment may be required; monitor patient condition. Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Naratriptan can interact with several medication classes; awareness of interaction severity is essential.

Major Interactions (Avoid): - Other triptans or ergotamine derivatives: combined use can cause excessive vasoconstriction. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive effects. - CYP1A2 inhibitors (e.g., fluvoxamine): can increase naratriptan plasma levels. - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy.